IceCure Medical (ICCM) U.S. Installed Base Jumps 70% After FDA Kidney Cancer Clearance

IceCure Medical Ltd. (ICCM) reported a 70% surge in its U.S. installed base of ProSense cryoablation systems, following FDA clearance last week for treating kidney cancer. The company's stock soared 284% on June 17, 2026, reaching $1.90 per share after the announcement. The FDA clearance, granted in the week of June 9, 2026, expands the indications for IceCure's liquid nitrogen-based cryoablation technology to include kidney tumors. This marks a significant expansion into the U.S. market, which represents a substantial portion of the global cryoablation market. IceCure's first-quarter revenue, reported earlier, increased 30% year-over-year to $1.3 million. The company aims to capitalize on the new FDA approval to further accelerate adoption and revenue growth for its minimally invasive cancer treatment solution.